Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about LTGO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Acetaminophen | Acute Pain | Phase 2 · NCT07102459 | Completed |
| Experimental: LTG-001 High Dose | Acute Pain | Phase 2 · NCT07102459 | Completed |
| LTG-001 | Acute Pain, Postoperative | Phase 2 · NCT06774625 | Completed |
| LTG-001 Mid Dose | Acute Pain, Postoperative | Phase 2 · NCT06774625 | Completed |
| LTG-001 Formulation A Prototype 1 | Pain Management | Phase 1 · NCT07341152 | Completed |
| LTG-001 SDD | Pain Management | Phase 1 · NCT07341152 | Completed |
| LTG-305 | Healthy | Phase 1 · NCT06554574 | Completed |
| LTG-321 | PK Drug-drug Interaction Study | Phase 1 · NCT07915947 | Not yet recruiting |
Also used in these trials (approved or third-party drugs, not LTGO's own candidates): Suzetrigine, Itraconazole, Pregabalin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
LTGO holds $401.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $19.7M/quarter from operations, an estimated runway of 61 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plans, we estimate that our cash and cash equivalents will be sufficient to fund our projected operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LTGO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Dr. Beth C. Seidenberg | 5%+ holder (13G) | 13,199,669 | 19.91% | 2026-09-30 |
| 5AM Ventures VI, L.P. 10% owner |
Insider | 7,325,962 | 11.05% | 2026-08-10 |
| Kush Parmar | 5%+ holder (13G) | 7,325,962 | 11.05% | 2026-09-30 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 5,295,690 | 7.99% | 2026-08-10 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 4,446,656 | 6.71% | 2026-08-07 |
| Blue Owl Capital Holdings LP | 5%+ holder (13G) | 3,596,780 | 5.43% | 2026-09-30 |
| James B. Tananbaum Director, 10% owner |
Insider | 3,414,544 | 5.15% | 2026-08-10 |
| Foresite Capital Management V, LLC 10% owner Includes shares also reported by James B. Tananbaum, counted once |
Insider | 3,414,544 | 5.15% | 2026-08-10 |
| Westlake BioPartners Fund I, L.P. 10% owner |
Insider | 2,094,813 | 3.16% | 2026-08-10 |
| Beth C Seidenberg Director, 10% owner Includes shares also reported by Westlake BioPartners Fund I, L.P., counted once |
Insider | 2,094,813 | 3.16% | 2026-08-10 |
| Sanofi 10% owner |
Insider | 672,788 | 1.01% | 2026-08-10 |
| Nima Farzan President and CEO, Director |
Insider | 114,453 | 0.17% | 2026-08-06 |
Share count 66,299,347 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LTGO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →